Swiss-British pharma giant focused on oncology, cardiovascular and more
A wave of market rotation has seen memory and chipmakers rally as big-tech hyperscalers pull back on AI capex. The Magnificent Seven lag as investors reassess profitability, memory costs rise, and demand for AI infrastructure remains heated. Investors seek clarity on monetization and future AI spending.
AstraZeneca has seen its shares fall after its heart-disease drug Wainua failed to meet the primary endpoint in a late-stage trial, undermining expectations of peak sales and pressuring the company ahead of 2030 targets. The results were disclosed by the company and followed by market analysts.
A roundup of recent cancer breakthroughs highlights new immunotherapies, targeted drugs and surgical-sparing treatments. The Independent reports on Scolyer’s pioneering work and a landmark NICE decision; The Guardian covers durvalumab’s promise in bladder cancer; Business Insider UK and Reuters summarize ASCO findings on pancreatic and colon cancers, among others.
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
Anthropic is launching an internal drug-discovery program to develop AI tools for life sciences, focusing on neglected diseases. The effort aims to create drug-discovery capabilities in-house and partner with industry, while navigating the costly regulatory path and uncertain clinical development timelines.
The UK–US pharmaceutical deal has led to a BMJ analysis predicting the NHS will divert billions to fund new medicines, risking hundreds of thousands of excess deaths by 2036, with the toll higher if social care funding is included.